Review articlePublished 15 Sep 2021

Critically Analyse the Historical and Economic Contexts of Aesthetic Practice

Authors: Haroon Hamid

Journal of Aesthetic & Reconstructive Surgery

Volume 7 · Issue 6 · Pages 45

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Botulinum Toxin is produced by Clostridium botulinum, a gram-positive anaerobic bacterium. The first case of Botulism was believed to have occurred in Germany in 1793 a rare and potentially fatal illness causing weakness, blurred vision and neurological manifestations that can lead to respiratory failure. Commonly acquired through ingestion of contaminated or improperly processed food and from wound infection. This toxin exists in eight distinct forms; A to G, with A, B, E & F causing Human botulism. The same organism, Clostridium botulinum type A (BoNTA) has been cultivated and is a widely used therapeutic and cosmetic agent. It is the core component of “BOTOX®”- the infamous tradename for anti-wrinkle injection treatment. Beyond cosmetic use, BoNTA has numerous therapeutic uses; migraines, spastic disorders, bruxism, hyperhidrosis and cerebral palsy are just a handful of examples. In the past decade cosmetic use propelled its popularity; used to treat glabellar “lines, the frontalis muscle, peri-orbital lines, gummy smile and masseter muscle hypertrophy”. Whilst Botulinum Toxin was known about as early as the 1700’s and has been refined over time to produce a safe and widely used products today- the history of Dermal Fillers and their role in cosmetics and therapeutic Medicine is much shorter. First discovered in 1970s, when animal Collagen and in particular Bovine Collagen was used as the basis of collagen injections and implants. Being a foreign body, adverse reactions and rejection was high with numerous complications experienced. It was not until the discovery and implementation of Hyaluronic Acid; an already abundant substance in the human body in Dermal Fillers that increased its safety profile and subsequently popularity. Similar to BoNTA, Dermal Filler treatment has had a role to play in clinical and cosmetic treatments. HA plays a key role in “tissue injury, regulating tissue repair and disease processes, such as activation of inflammatory cells to mount an innate response to injury” whilst also providing “protection against tissue damage” and “promotes (tissue) regeneration and repair”. In the Aesthetic industry it plays a central role in ‘volume replacement’ and is widely used to treat lines and reshape the face. The premise of dermal filler treatment in aesthetics is to use high concentration of Hyaluronic Acid to replace lost collagen or to increase tissue volume- depending on the treatment requested and client desired outcome. This essay will explore the development of BoNTA & dermal fillers and how they have been adapted for therapeutic and cosmetic use, thereby making them one of the most versatile and popular treatments today and being the core component of a multi-billion-pound industry.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

More from this journal

The newest in Journal of Aesthetic & Reconstructive Surgery.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Aesthetic & Reconstructive Surgery
  • SubjectSurgery
  • SubjectDermatology
  • BylineArticles whose byline prints “Haroon Hamid”